TCF7L2 promotes beta cell regeneration in human and mouse pancreas
Diabetes is characterised by loss and dysfunction of the beta cell. A major goal of diabetes therapy is to promote the formation of new beta cells. Polymorphisms of T cell factor 7-like 2 (TCF7L2) are associated with type 2 diabetes, negatively regulating beta cell survival and function. Here, we provide evidence for a role of TCF7L2 in beta cell proliferation and regeneration.
Pancreatic sections from three mouse models (high-fat diet, exendin-4 and streptozotocin-treated mice) and from healthy individuals and patients with type 2 diabetes were used to investigate the association of beta cell regeneration and TCF7L2 levels. To analyse a direct effect of TCF7L2 on duct cell to beta cell conversion, TCF7L2 was overexpressed in isolated exocrine cells.
TCF7L2 levels correlated with beta cell compensation during high-fat diet feeding. TCF7L2 was increased together with pancreatic duct cell proliferation and differentiation. Small islet-like cell clusters (ICCs) that contained TCF7L2 originated in the vicinity of the ductal epithelium. In human isolated exocrine tissue, TCF7L2 overexpression induced proliferation of pancreatic duct cells and ICC formation next to duct cells, an effect dependent on the JAK2/STAT3 pathway.
The present study demonstrates that TCF7L2 overexpression fosters beta cell regeneration. Our findings imply correlation of TCF7L2 levels and new beta cell formation.
- TCF7L2 promotes beta cell regeneration in human and mouse pancreas
Volume 55, Issue 12 , pp 3296-3307
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Beta cell regeneration
- Industry Sectors
- Author Affiliations
- 1. Centre for Biomolecular Interactions Bremen, University of Bremen, Leobener Straße NW2, Room B2080, 28359, Bremen, Germany
- 2. Jiangsu Provincial Academy of Chinese Medicine, Nanjing, People’s Republic of China
- 3. Competence Center for Clinical Studies Bremen, University of Bremen, Bremen, Germany
- 4. Division of Transplantation, University of Illinois at Chicago, Chicago, IL, USA
- 5. Thérapie Cellulaire du Diabète, Inserm/Université de Lille Nord de France, Lille, France